Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alfred N Poindexter

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Maturitas|June 27, 2006
Physicians' views and practices concerning menopausal hormone therapyHaleh Sangi-Haghpeykar, Alfred N Poindexter
Perspectives on Sexual and Reproductive Health|December 29, 2005
Consistency of condom use among low-income hormonal contraceptive usersHaleh Sangi-Haghpeykar, Samuel F Posner, Alfred N Poindexter
Maternal and Child Health Journal|June 21, 2005
Paternal influences on the timing of prenatal care among HispanicsHaleh Sangi-Haghpeykar, Mina Mehta, Sam Posner, et al.
Contraception|July 25, 2006
Disparities in contraceptive knowledge, attitude and use between Hispanic and non-Hispanic whitesHaleh Sangi-Haghpeykar, Nina Ali, Sam Posner, et al.
International Journal of Fertility and Women'S Medicine|September 19, 2003
Cycle control, tolerability, and satisfaction among women switching from 30-35 microg ethinyl estradiol-containing oral contraceptives to the triphasic norgestimate/25 microg ethinyl estradiol-containing oral contraceptive Ortho Tri-Cyclen LOAlfred N Poindexter, Ronald Burkman, Alan C Fisher, et al.
Obstetrics and Gynecology|November 11, 2022
Long-term Relugolix Combination Therapy for Symptomatic Uterine LeiomyomasAyman Al-Hendy, Andrea S Lukes, Alfred N Poindexter, et al.
Contraception|December 1, 2020
Efficacy, safety, and tolerability of a levonorgestrel/ethinyl estradiol transdermal delivery system: Phase 3 clinical trial resultsAnita L Nelson, Andrew M Kaunitz, Robin Kroll, et al.
Pain Management|May 15, 2023
A plain language summary of the safety of relugolix combination therapy and improvement in symptoms in women with uterine fibroids from the LIBERTY 1 and LIBERTY 2 studiesAyman Al-Hendy, Andrea S Lukes, Alfred N Poindexter, et al.
The New England Journal of Medicine|February 17, 2021
Treatment of Uterine Fibroid Symptoms with Relugolix Combination TherapyAyman Al-Hendy, Andrea S Lukes, Alfred N Poindexter, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 19, 2003
Safety and acceptability of penile application of 2 candidate topical microbicides: BufferGel and PRO 2000 Gel: 3 randomized trials in healthy low-risk men and HIV-positive menStephen R Tabet, Marianne M Callahan, Christine K Mauck, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Maturitas|June 27, 2006
Physicians' views and practices concerning menopausal hormone therapyHaleh Sangi-Haghpeykar, Alfred N Poindexter
Perspectives on Sexual and Reproductive Health|December 29, 2005
Consistency of condom use among low-income hormonal contraceptive usersHaleh Sangi-Haghpeykar, Samuel F Posner, Alfred N Poindexter
Maternal and Child Health Journal|June 21, 2005
Paternal influences on the timing of prenatal care among HispanicsHaleh Sangi-Haghpeykar, Mina Mehta, Sam Posner, et al.
Contraception|July 25, 2006
Disparities in contraceptive knowledge, attitude and use between Hispanic and non-Hispanic whitesHaleh Sangi-Haghpeykar, Nina Ali, Sam Posner, et al.
International Journal of Fertility and Women'S Medicine|September 19, 2003
Cycle control, tolerability, and satisfaction among women switching from 30-35 microg ethinyl estradiol-containing oral contraceptives to the triphasic norgestimate/25 microg ethinyl estradiol-containing oral contraceptive Ortho Tri-Cyclen LOAlfred N Poindexter, Ronald Burkman, Alan C Fisher, et al.
Obstetrics and Gynecology|November 11, 2022
Long-term Relugolix Combination Therapy for Symptomatic Uterine LeiomyomasAyman Al-Hendy, Andrea S Lukes, Alfred N Poindexter, et al.
Contraception|December 1, 2020
Efficacy, safety, and tolerability of a levonorgestrel/ethinyl estradiol transdermal delivery system: Phase 3 clinical trial resultsAnita L Nelson, Andrew M Kaunitz, Robin Kroll, et al.
Pain Management|May 15, 2023
A plain language summary of the safety of relugolix combination therapy and improvement in symptoms in women with uterine fibroids from the LIBERTY 1 and LIBERTY 2 studiesAyman Al-Hendy, Andrea S Lukes, Alfred N Poindexter, et al.
The New England Journal of Medicine|February 17, 2021
Treatment of Uterine Fibroid Symptoms with Relugolix Combination TherapyAyman Al-Hendy, Andrea S Lukes, Alfred N Poindexter, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 19, 2003
Safety and acceptability of penile application of 2 candidate topical microbicides: BufferGel and PRO 2000 Gel: 3 randomized trials in healthy low-risk men and HIV-positive menStephen R Tabet, Marianne M Callahan, Christine K Mauck, et al.
Pageof 1